Aarti Pharmalabs Limited (NSE: AARTIPHARM)

Market Cap	53.02B
Revenue (ttm)	19.68B
Net Income (ttm)	2.28B
Shares Out	90.63M
EPS (ttm)	25.16
PE Ratio	23.25
Forward PE	n/a
Dividend	2.00 (0.34%)
Ex-Dividend Date	Jul 31, 2024

Volume	96,774
Open	573.15
Previous Close	578.65
Day's Range	571.50 - 589.90
52-Week Range	399.55 - 721.70
Beta	n/a
Analysts	n/a
Price Target	n/a
Earnings Date	Jan 27, 2025

About Aarti Pharmalabs

Aarti Pharmalabs Limited, together with its subsidiaries, engages in the manufacture and sale of active pharmaceutical ingredients, pharmaceutical intermediates, and xanthine derivatives in India and internationally. The company offers active pharmaceutical ingredients for various therapeutic areas, such as cardiovascular, anti-asthmatic, anti-cancer, anti-coagulant, anti-diabetic, arthritis, central nervous system (CNS) agents, skincare, overactive bladder, calcimimetic, decongestant, anti-thalassaemic, analgesic, and ophthalmologic medication...

• Industry: Drug Manufacturers - Specialty & Generic
• Sector: Healthcare
• Founded: 2019
• Employees: 2,095
• Stock Exchange: National Stock Exchange of India
• Ticker Symbol: AARTIPHARM

Financial Performance

In 2023, Aarti Pharmalabs's revenue was 18.53 billion, a decrease of -4.76% compared to the previous year's 19.45 billion. Earnings were 2.17 billion, an increase of 12.10%.